| Literature DB >> 36135069 |
Stephanie J Kendall1,2, Jodi E Langley2,3, Mohsen Aghdam1,2, Bruce N Crooks2,4, Nicholas Giacomantonio5, Stefan Heinze-Milne2,6, Will J Johnston1,2, Melanie R Keats1,2,7, Sharon L Mulvagh5, Scott A Grandy1,2,5,6,7.
Abstract
Childhood and adolescent cancer survivors are disproportionately more likely to develop cardiovascular diseases from the late effects of cardiotoxic therapies (e.g., anthracycline-based chemotherapy and chest-directed radiotherapy). Currently, dexrazoxane is the only approved drug for preventing cancer treatment-related cardiac damage. While animal models highlight the beneficial effects of exercise cancer treatment-related cardiac dysfunction, few clinical studies have been conducted. Thus, the objective of this scoping review was to explore the designs and impact of exercise-based interventions for managing cancer treatment-related cardiac dysfunction in childhood and adolescent cancer survivors. Reviewers used Joanna Briggs Institute's methodology to identify relevant literature. Then, 4616 studies were screened, and three reviewers extracted relevant data from six reports. Reviewers found that exercise interventions to prevent cancer treatment-related cardiac dysfunction in childhood and adolescent cancer survivors vary regarding frequency, intensity, time, and type of exercise intervention. Further, the review suggests that exercise promotes positive effects on managing cancer treatment-related cardiac dysfunction across numerous indices of heart health. However, the few clinical studies employing exercise interventions for childhood and adolescent cancer survivors highlight the necessity for more research in this area.Entities:
Keywords: adolescent; cancer; cancer survivor; cardiotoxicity; exercise; pediatric
Mesh:
Substances:
Year: 2022 PMID: 36135069 PMCID: PMC9497997 DOI: 10.3390/curroncol29090500
Source DB: PubMed Journal: Curr Oncol ISSN: 1198-0052 Impact factor: 3.109
Search Strategy for database search.
| 1 | (Cancer* OR Neoplas* OR Leukemia* OR Leukaemia* OR Tumor* OR Tumour* OR Lymphoma* OR Chemotherap* OR Malignanc* OR anthracycline* OR ‘Antineoplastic Agent*’ OR Immunotherap* OR ‘Monoclonal Antibod*’ OR ‘Tyrosine Kinase Inhibitor*’ OR Radiation OR Radiology) |
| 2 | Child* OR Adolescent* OR Teen* OR ‘Young Adult*’ OR ‘Early Child*’ OR Pediatric* OR Paediatric* OR Infant* OR Toddler* OR Bab* OR Juvenile* OR ‘Pre Pubescent*’ |
| 3 | 1 AND 2 |
| 4 | Exercise* OR ‘Resistance Training*’ OR Aerobic* OR ‘Motor Activity’ OR ‘Exercise Therap*’ OR ‘Physical Activit*’ OR Training OR ‘Physical Fitness’ OR Exertion OR Yoga OR Pilates OR ‘Dance Therap*’ OR ‘Tai Ji’ OR Qigong |
| 5 | Exp Exercise/ |
| 6 | 4 OR 5 |
| 7 | 3 AND 6 |
| 8 | Myocarditis* OR ‘Heart Failure’ OR Cardiotoxic* or Cardiomyopath* OR Heart* OR ‘Radiation Injury*’ |
| 9 | 7 AND 8 |
Figure 1PRISMA flow diagram of included studies.
Characteristics of included studies.
| Study Identification | Title | Country | Design | Aim | Criteria |
|---|---|---|---|---|---|
| Järvelä 2013 [ | Endothelial function in long-term survivors of childhood ALL: Effects of a home-based exercise program [ | Finland | Case-control study | Assess the effects of a home-based exercise intervention on endothelial structure in survivors of childhood ALL [ | Age < 16 years at diagnosis, currently age 16–30 years, first continuous remission without hematopoietic bone marrow transplantation, diagnosed in 1986 or later, treated according to the Nordic regimen [ |
| Long 2018 [ | Exercise training improves vascular function and secondary health measures in survivors of pediatric oncology related cerebral insult. | Australia | Cohort study | Assess the feasibility and effectiveness of a 24-week exercise intervention on cardiovascular health in childhood cancer survivors. | >5-year survivor of pediatric cancer-related cerebral insult, currently aged 15–23, not pregnant and without a current cardiovascular disease diagnosis. |
| Morales 2020 [ | Inhospital exercise benefits in childhood cancer: A prospective cohort study. | Spain | Cohort study | Assess the effects of aerobic and resistance training in children with leukemia receiving neoadjuvant or intensive chemotherapy. | Currently aged 4–18 years, received a new cancer diagnosis, diagnosed, treated, and followed at the Hospital Infantil Universitario Nino Jesus, and not currently participating in any other interventional trials. |
| Sharkey 1993 [ | Cardiac rehabilitation after cancer therapy in children and young adults. | United States | Case series | Assess childhood cancer survivors using exercise testing before and after a 12-week aerobic exercise program. | Received >100 mg/m2 of anthracyclines, post-pubertal, ≥1-year post-treatment, and no residual malignancies. |
| Smith 2013 [ | Exercise training in childhood cancer survivors with subclinical cardiomyopathy who were treated with anthracyclines. | United States | Case series | Assess the effects of a 12-week exercise program on anthracycline-treated childhood cancer survivors with subclinical cardiomyopathy. | 18 years of age, ≥10 years post-diagnosis of childhood cancer, treated with doxorubicin and/or daunorubicin, sedentary (<150 min of moderate-intensity physical activity per week), LVEF ≥ 40 and ≤55%, and not receiving cardiomyopathy treatment or received radiation therapy. |
Abbreviations: ALL, acute lymphoblastic leukemia; LV, left ventricle; LVEF, left ventricle ejection fraction; mg/m2, milligrams per meter squared.
Cancer participant characteristics.
| Study ID | Group | Participants (Number) | Anthracyclines Dosage (mg/m2) | Radiation Field (Gy) | Age (Years) | Time Since Diagnosis (Years) | Cancer Type |
|---|---|---|---|---|---|---|---|
| Järvelä 2013 & 2016 [ | N/A | M=10 | n = 21 (Med = 240, range: 120–370) | n = 5 (unspecified dosage) | Med = 21.1 (range: 16.0–28.4) | Med = 15.9 (range: 11.3–21.4) | ALL |
| Long 2018 [ | N/A | M=6 | n = 4 (unspecified dosage) | n = 8 (unspecified dosage) | Med = 19 (range: 16–23) | Med = 15 (range: 7–22) | Brain = 9, ALL = 3, Other = 1 |
| Morales 2020 [ | Controls | M=63 | n = 41 | n = 30, (range: 1–≥50) | mean = 11 (range: 4–18) | On treatment | 15 various types |
| Exercise | M=61 | n = 27 (unspecified dosage | n = 27 (range: 1–≥50) | mean = 11 (range: 4–17) | |||
| Sharkey 1993 [ | N/A | M=5 | n = 10 (mean = 349 ± 69 | n = 9 (range: 18–55) | mean = 19+/−3 | mean = 11 (range: 4–18) | 5 various types |
| Smith 2013 [ | N/A | M=3 | n = 4 | n = 0 | Range: 33–41 | Range: 25–30 | Osteosarcoma = 4, Ewing sarcoma = 1 |
Abbreviations: N/A, not applicable; M, male; F, female; Med, median; mg/m2, milligrams per meter squared; Gy, Gray; ALL, acute lymphoblastic leukemia; mean.
Exercise intervention characteristics for childhood cancer survivors.
| Study ID | Mode | Frequency (Sessions/Week) | Intensity | Time (min) | Type | Location | Duration (Weeks) | Instructor |
|---|---|---|---|---|---|---|---|---|
| Järvelä 2013 & 2016 [ | Resistance | 3–4 | 3 sets, as many repetitions as possible, no rest stated. | Not stated | Eight exercises to strengthen the gluteal, lower limb, shoulders, upper limb, abdominal, and back muscles. | Home | 12 | Experts in sports science |
| Aerobic | At least 3 | Not specified | 30 | Participant choice (i.e., walking or jogging). | ||||
| Long 2018 [ | Resistance | 2 to 3 | 3 sets, 10 repetitions, 60–70% 3-RM, with 3 to 5 min of rest between exercises. | 75–80 | Circuit including 6 to 10 exercises targeting the chest, back, shoulders, arms, and legs. | Not stated | 24 | Exercise physiologist |
| Aerobic | 2 to 3 | 40–60% HRmaxwith individualized progressive increase. | 10–15 | Three sets of 4 consecutive sprint-rest bouts, with 3 to 5 min of rest between each set. Rowing ergometer, stationary bike, or arm ergometer. | ||||
| Morales 2020 [ | Resistance | 2 to 3 | 1 to 3 sets of 6–15 repetitions, 5% to 10% load increases as needed with 1 min rest between sets. | 30 | Shoulder, chest and leg press, side-arm rowing extension and flexion, knee extension and flexion and abdominal, lumbar and shoulder adduction. | Hospital | Med duration 22 weeks (IQR: 14, 28) | Exercise physiologist |
| Aerobic | 2 to 3 | 65–80% HRreserve with individualized progressive increase. | 30–40 | Ten minutes each of cycle ergometer leg pedalling, treadmill running, or arm cranking in those missing a lower limb. Ten minutes of aerobic games. | ||||
| Sharkey 1993 [ | Aerobic | Two sessions for weeks 1–6 and 3 sessions for weeks 7–12. | 60% to 80% HRmax progressive increase. | 45–60 | Not stated | Hospital and home | 12 | Not stated |
| Smith 2013 [ | Resistance | 3–5 | 1 set of 12–15 repetitions on 8 to 10 exercises. | Not stated | Not stated | Home | 12 | Exercise physiologist |
| Aerobic | 2–3 | 40–70%HRreserve. | 20–45 | Not stated |
Abbreviations: min, minutes; Min, minimum; Max, maximum; RM repetitions maximum; reps, repetitions; HR, heart rate; HRR, heart rate reserve; Med, median; IQR, interquartile range.3.5 Key findings of the included studies relating to heart health.
Key cardiovascular health-related findings.
| Study ID | LVEF | Valve | Strain | FS | CI | SV |
|---|---|---|---|---|---|---|
| Järvelä 2013 & 2016 [ |
|
| N/A | N/A | ||
| Long 2020 [ | N/A | N/A | N/A | N/A | N/A | N/A |
| Morales 2020 [ | N/A | N/A | N/A | N/A | ||
| Sharkey 1993 [ | N/A | N/A | N/A | N/A |
|
|
| Smith 2013 [ | N/A | N/A | N/A | N/A | N/A |
Abbreviations: , insignificant change; ↑, improvement , significant change; LVEF, left ventricle ejection fraction; FS, fractional shortening; CI, cardiac index; SV, stroke volume; N/A, not applicable.
Key periphery cardiovascular health findings.
| Study ID | IMT | FMD | Oxygen Pulse |
|---|---|---|---|
| Järvelä 2013 & 2016 [ | N/A | ||
| Long 2020 [ | N/A | N/A | |
| Morales 2020 [ | N/A | N/A | N/A |
| Sharkey 1993 [ | N/A | N/A | N/A |
| Smith 2013 [ | N/A | N/A |
Abbreviations: , significant change IMT, intima-media thickness; FMD, flow-mediated dilation; NA, not applicable; ↑, increased; ↓, decreased.